
Shefali Jariwala death: What it reveals about fake cosmetologists
While the Indian Association of Dermatologists, Venereologists, and Leprologists (IADVL) is raising the issue and writing to health officials, we need the public to stop enabling this madness.
There is absolutely no degree called 'cosmetology'. Yet, the business continues to flourish in India, the only country where people die from hair transplants. In May, Anushka Tiwari, a Kanpur-based dentist, was arrested after two men died following hair transplant procedures performed by her. It's a crisis.
What happened to actor-model Shefali Jariwala should never have happened. As a dermatologist with over 14 years of experience, I've watched in horror as unqualified practitioners turn anti-ageing treatments into a deadly gamble. This isn't just tragic—it's criminal.
How to spot a fake doctor before it's too late
It doesn't matter how convincing an Instagram ad looks—always verify your doctor's credentials. Here's how:
Go to your state medical council's website. Search the doctor's name. Check their MBBS degree and specialisation.
If they're not listed, run. If someone calls themself a 'cosmetologist' without a medical degree to show for it, run faster.
Also read: Is 30 a good age to start using anti-ageing products? Here are some dos and don'ts
Glutathione scam: Online buying is Russian roulette
Every week, young women walk into my clinic with glutathione vials bought from IndiaMart or some shady online sellers, expecting me to inject them. My answer? Absolutely not.
You don't know if the cold chain was maintained.
You don't know if it's counterfeit.
You don't know if it's even safe for human use.
Glutathione is a powerful antioxidant, but when misused—especially in unregulated doses for years—it can turn toxic. According to media reports, Shefali had been on these injections for five to six years. Was it under a dermatologist's supervision? Was it even real glutathione? We may never know.
Golden rule you must remember
It's not about avoiding treatments—it's about respecting them. Here's my professional mantra:
A qualified dermatologist knows:
Precise dosing – When glutathione is life-saving vs. when it's toxic
Contraindications – Who should never receive certain treatments
Emergency protocols – What to do when things go wrong (because sometimes they do)
Also read: Debunking anti-ageing myths. Treatments, luxury creams can't rewind the biological clock
Anti-ageing done right vs reckless experimentation
Anti-ageing medicine isn't the villain—quacks are. When performed by licensed dermatologists, treatments like NAD drips, NMN, and even glutathione are safe. But here's what else you need:
A balanced lifestyle – No injection replaces sleep, nutrition, and exercise.
Realistic expectations – Aging is natural; our goal is healthy aging, not magic.
Zero tolerance for non-doctors – Dentists doing Botox? A disaster waiting to happen.
Plea to the public: Stop trusting social media over science
Good dermatologists don't have flashy Instagram ads because we're too busy treating patients. Meanwhile, quacks spend fortunes on SEO, luring victims with cheap prices and empty promises.
'Anti-ageing means prolonging life—not losing it to negligence. If Shefali's death exposes unqualified practitioners, let it be a turning point,' said Dr Rajiv Sharma, president of IADVL.
So TL;DR:
Never let a non-dermatologist inject you. Ever. Never buy medications online from platforms like Amazon Never ever prioritise trends over safety.
Shefali Jariwala's death should be a wake-up call. Demand accountability. Choose wisely. And please stop letting influencers play doctor.
Dr Deepali Bhardwaj is a Consultant Dermatologist, Max Hospital, Saket. She is also an anti-allergy specialist, laser surgeon and internationally trained aesthetician. She tweets @dermatdoc. Views are personal.
(Edited by Prashant)
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Hindustan Times
27 minutes ago
- Hindustan Times
Rajasthan govt official set himself on fire over work stress; in critical condition
An administrative officer at a government school in Rajasthan's Didwana-Kuchaman district allegedly attempted to kill self due to work-related stress on Monday, police said. Preliminary investigation suggests that the man was under severe pressure to update departmental records and meet administrative work targets.(Representative Image/Pixabay) The incident took place in the veranda of the Government Higher Secondary School in Makrana town when Ramavtar Sharma (58), posted as the administrative officer, arrived on the premises carrying petrol in a plastic bottle, a police officer said. He poured the petrol on himself and set himself on fire within the school premises, Station House Officer (SHO) Suresh Soni said. A female sweeper working nearby noticed him engulfed in flames and raised an alarm, alerting other staff members. She rushed outside screaming for help. Locals and school staff took Sharma to the government sub-district hospital on a motorcycle, Soni said. Javed Alam, posted at the sub-district hospital, said the Sharma was given first aid. "Due to the severity of burns and his critical condition, he was referred to Jawaharlal Nehru Hospital in Ajmer for advanced treatment," he said. Preliminary investigation suggests that he was under severe pressure to update departmental records and meet administrative work targets, police said. An inquiry has been initiated and statements of staff and family members are being recorded to ascertain the exact cause behind the suicide attempt, they added. Discussing suicides can be triggering for some. However, suicides are preventable. A few major suicide prevention helpline numbers in India are 011-23389090 from Sumaitri (Delhi-based) and 044-24640050 from Sneha Foundation (Chennai-based).
&w=3840&q=100)

Business Standard
an hour ago
- Business Standard
KKR's exit from JB Chemicals cements its healthcare track record
KKR & Co's ₹11,900 crore ($1.42 billion) exit from JB Chemicals and Pharmaceuticals marks another successful bet in India's fast-growing healthcare sector, underscoring the US-based private equity giant's strong track record in the space. KKR exited JB Chemicals on Sunday. The sale of its 46.39 per cent stake in JB Chemicals to Torrent Pharmaceuticals comes over four years after KKR acquired control of the company in 2020. The exit follows its blockbuster five-time (5x) return in Max Healthcare in 2022, which remains the largest block deal by a private equity firm in India to date, a person familiar with the matter said. In JB Chemicals, the US-based firm made 36 per cent gross internal rate of return in the exit, including sale of part of its stake via block deal early this year. The JB Chemicals deal adds to KKR's expanding healthcare portfolio in India, which includes stakes in Healthcare Global Enterprises, Baby Memorial Hospital (BMH), Healthium Medtech, and Infinx Healthcare, a US-based healthcare technology firm focused on revenue cycle and patient access solutions. Since the start of 2024, KKR's private equity arm has deployed $2 billion in India. In June, the firm arranged $600 million in financing for the Manipal group through KKR Capital Markets. The deal, anchored by KKR's private credit and insurance platforms, is aimed at supporting Manipal's long-term growth strategy. The Manipal group, which operates Manipal Health Enterprises, one of India's largest multispecialty hospital chains, has been active in the M&A (mergers and acquisitions) market. Manipal had in April 2023 sold a significant stake in its hospital business to Singapore's Temasek Holdings in a transaction valued at nearly $2 billion. KKR's back-to-back healthcare bets come amid rising investor appetite for India's healthcare sector, fuelled by growing demand for quality care, rising incomes, and increased insurance penetration. In 2024, healthcare funding saw an 80 per cent rise in deal volumes, with notable activity in medtech and single-specialty hospitals. The IT/ITeS sector deal value grew 300 per cent, driven by major transactions such as Perficient ($3 billion), Altimetrik ($900 million), and GeBBS ($865 million). Single-specialty hospitals saw particular interest, with deal volumes doubling as investors targeted underpenetrated categories such as eyecare, oncology, and IVF, as per a report by Bain & Company.
&w=3840&q=100)

Business Standard
an hour ago
- Business Standard
Biological E to make HPV9 vaccine under licensing pact with Recbio
Hyderabad-based vaccine manufacturer Biological E (BE) on Monday announced it has entered a licensing agreement with Chinese pharma firm Jiangsu Recbio Technology Company to produce and commercialise Recbio's nine-valent Human Papillomavirus (HPV9) vaccine for India and global markets. The HPV9 vaccine, designed to protect against nine HPV types linked to cervical, vulvar, vaginal, anal and oropharyngeal cancers, as well as genital warts, is currently in Phase 3 clinical trials in China. As part of the agreement, BE will receive the exclusive right to commercialise the vaccine in India and participate in UNICEF and PAHO tenders in other markets. Recbio will also provide BE with the drug substance (DS) and transfer the technology to formulate, fill, and package the vaccines. 'It will also include technology transfer for DS production at an appropriate time in the future,' Recbio said in a statement. In India, the estimated number of deaths due to cervical cancer stood at 35,691 in 2023, up from 34,806 in 2022 and 33,938 in 2021, according to a parliamentary response by the Union Health Ministry. Recbio claims that the nine-valent HPV vaccine is effective in preventing around 90 per cent of cervical cancers and 90 per cent of anal and genital warts. Commenting on the collaboration, Mahima Datla, Managing Director at BE, said the partnership aligns with the company's commitment to improve global health by making essential vaccines more accessible and affordable. The collaboration also marks a significant milestone for Recbio in entering the Indian and international markets, highlighting its potential in the innovative vaccine field. Liu Yong, Founder, Chairman and Chief Executive Officer (CEO) of Recbio, added that it will work together with BE to accelerate the launch process of the HPV9 vaccine in India. Following the signing of the technology licence agreement between the two companies, Recbio has begun transferring the necessary technical knowledge, materials, and expertise to BE to produce the HPV9 vaccine. BE is expected to begin large-scale manufacturing of the HPV9 vaccine once the technology transfer is completed. Currently, BE supplies its vaccines to more than 140 countries, and its therapeutic products are sold in India, the US and Europe. It had recently received approval for India's first 14-valent Pneumococcal Conjugate Vaccine.